Efficiency and safety of lipid-lowering therapy for chronic kidney disease


Cite item

Full Text

Abstract

The paper considers the problem of lipid-lowering therapy for chronic kidney disease, by using different groups of drugs, the expediency, efficiency, and safety of the therapy at different disease stages, including end-stage renal failure, and replacement treatments.

Full Text

Эффективность и безопасность гиполипидемической терапии при хронической болезни почек. - Аннотация. Рассматриваются проблема гиполипидемической терапии хронической болезни почек с применением препаратов различных групп, целесообразность, эффективность и безопасность такой терапии на разных стадиях заболевания, включая терминальную стадию почечной недостаточности и лечение заместительными методами.
×

References

  1. Hostetter T.H. Chronic Kidney Disease Predicts Cardiovascular Disease. N Engl J Med 2004; 351: 1344-1346.
  2. Schiffrin E.L., Lipman M.L., Mann J.F. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007; 116: 85-97.
  3. Vaziri N.D. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences Am J Physiol Ren Physiol 2005; 290: F262-F272.
  4. Fried L.F., Orchard T.J., Kasiske B.L. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001; 59: 260-269.
  5. Schaeffner S., Kurth T., Curhan G.C. et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 2003; 14: 2084- 2091.
  6. Muntner P., Coresh J., Smith J.C. et al. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int 2000; 58: 293-301.
  7. Chen J., Muntner P., Hamm L.L. et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 2004; 140 (3): 167.
  8. Tanaka H., Shiohira Y., Uezu Y. et al. Metabolic syndrome and chronic kidney disease in Okinawa, Japan. Kidney Int 2006; 69 (2): 369-374.
  9. Kopple J.D., Feroze U. The effect of obesity on chronic kidney disease. J Ren Nutr 2011; 1 (1): 66-71.
  10. Колина И.Б. Влияние нарушений липидного обмена на течение и прогноз хронического гломерулонефрита с нефротическим синдромом: Дис. ... канд. мед. наук. М 2002.
  11. Wanner C., Krane V., Marz W. et al. Atorvastatin in patients with Type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353 (3): 238-248.
  12. Fellstrom B.C., Jardine A.G., Schmieder R.E. et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360 (14): 1395-1407.
  13. Strippoli G.F.M., Navaneethan S.D., Johnson D. et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ 2008; 336 (7645): 645-651.
  14. Shiomi M., Ito T., Tsukada T. et al. Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques. Effect of pravastatin sodium on atherosclerotic mature WHHL rabbits. Arterioscl Thromb Vase Biol 1995; 15: 1938-1944.
  15. Crisby M., Nordin-Fredriksson G., Shah P.K. et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001; 103: 926-933.
  16. Muntner P., He J., Astor B.C. et al. Traditional and nontraditional risk factors predict сoronary heart disease in chronic kidney disease: results from the Atherosclerosis Risk in Communities Study. J Am Soc Nephrol 2005; 16: 529-538.
  17. Douglas K., O'Malley P.G., Jackson J.L. Meta-Analysis: The Effect of Statins on Albuminuria. Ann Intern Med 2006; 145: 117-124.
  18. Palinski W. Immunomodulation: a new role for statins? Nature Med 2000; 12: 1311-1312.
  19. Rosenson R.S., Tangney C.C., Casey L.C. Inhibition of proinflammatory cytokine production by pravastatin. Lancet 1999; 353: 983-984.
  20. Zelvyte I., Dominaitiene R., Crisby M., Janciauskiene S. Modulation of inflammatory mediators and PPARgamma and NFkappaB expression by pravastatin in response to lipoproteins in human monocytes in vitro. Pharmacol Res 2002; 45 (2): 147-154.
  21. Колина И.Б., Ставровская Е.В., Шилов Е.М. Materia Мedica 2003; 37 (1): 31.
  22. Kasiske B.L., Wanner C., O'Neill W.Ch. An Assessment of Statin Safety by Nephrologists. Am J Cardiol 2006; 97 (8A): 82С-85С.
  23. Laaksonen R., Tarasov K., Kauhanen D. et al. Plasma Eicosanoids are Potential Biomarkers for Muscle Weakness and Pain related to Statin Treatment. Circulation 2011; 124: A14888.
  24. Chapman M.J. Pharmacology of fenofibrate. Am J Med 1987; 83: 21-25.
  25. Davidson M. H., Armani A., McKenney J.M., Jacobson T. A. Safety considerations with fibrate therapy. Am J Cardiol 2007; 99: 3-18.
  26. Bruckert E., Labreuche J., Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 2010; 2: 353-361.

Copyright (c) 2013 Kolina I.B., Stavrovskaia E.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

© 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies